Compare Adaptive Biotechnologies Corp (ADPT) vs Rigetti Computing Inc (RGTI) Price & Performance

Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.

The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.

Rigetti Computing (RGTI) trades at $18.42, up 4.36% on the day, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company reported Q2 2026 revenue growth of 185% to $5.1 million, beating estimates, but posted a net loss of $0.05 per share, missing expectations. Despite heavy operating losses and negative margins, analyst sentiment remains strongly positive with 85.7% recommending Buy, driven by government backing and quantum computing potential.

The outlook for RGTI is high-risk, high-reward, offering exposure to the emerging quantum computing sector with significant government and commercial interest. However, persistent negative profitability, high cash burn, and intense competition from peers like IonQ pose substantial risks to shareholder value. Investment suitability is limited to those tolerant of speculative, early-stage company volatility.